Forekomsten af tilbagefald ved 5 år var reduceret hos de patienter som fik TAC, sammenlignet med dem, som fik FAC (henholdsvis 25% versus 32%).
Incidence of relapses at 5 years was reduced in patients receiving TAC compared to those who received FAC (25% versus 32%, respectively) i. e. an absolute risk reduction by 7% (p = 0.001).